ATA-100 is under clinical development by Atamyo Therapeutics and currently in Phase II for Limb-Girdle Muscular Dystrophy. According to GlobalData, Phase II drugs for Limb-Girdle Muscular Dystrophy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ATA-100 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ATA-100 overview
ATA-100 is under development for the treatment of limb-girdle muscular dystrophy type 2 (LGMD2I). It comprises adeno associated virus (AAV) expressing fukutin-related protein (FKRP). It is administered through intravenous route.
Atamyo Therapeutics overview
Atamyo Therapeutics is focused on the development of effective and safe gene therapies for neuromuscular diseases. Atamyo Therapeutics is headquartered in Paris, France.
For a complete picture of ATA-100’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
